Regulus Therapeutics (United States)
Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Regulus Therapeutics (United States), United States, covering academic research published from 2008 to 2025. Read More.
Open Access Percentage
50%
Total
Publications
177
Total Open
Publications
89
Total
Citations
23K
Open Access
Percentage
50%
Total
Publications
177
Total Open
Publications
89
Total
Citations
23K
Breakdown
Publisher Open
15%
Both
26%
Other Platform Open
10%
Closed
49%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 37%
27
Hybrid 16%
12
No Guarantees 47%
35
Other Platform Open
Domain 80%
51
Institution 50%
32
Preprint 6%
4
Public 5%
3
Other Internet 5%
3
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 51 |
doaj.org OAI-PMH Repository | Institution | 10 |
Harvard University | Institution | 4 |
bioRxiv | Preprint | 4 |
Figshare | Public | 3 |
DOI | Other Internet | 3 |
California Digital Library | Institution | 3 |
Unknown Repository | Other Internet | 2 |
University of Groningen | Institution | 2 |
Royal Netherlands Academy of Arts and Sciences | Institution | 2 |